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Abstract
Background: The plasticizer di-(2-ethylhexyl) phthalate (DEHP) has been shown to stimulate a
non-allergy related immune response with increased levels of IgG1 and IgG2a, but not IgE, after co-
administration with the model allergen ovalbumin (OVA) in mice. In mice, decreased IgG1 and
increased IgG2a have been associated with the development of mucosal tolerance towards inhaled
allergens. As DEHP selectively promote formations of IgG1 and IgG2a without stimulating the IgE
response, it was hypothesized that DEHP may suppress an established IgE mediated allergic
response. Mice pre-sensitised to OVA were repeatedly co-exposed to DEHP and OVA and the
effects were evaluated on the levels of OVA-specific antibodies, ex vivo cytokine levels and the
degree of lung inflammation after challenge with an OVA aerosol.
Findings: Compared to the OVA-sensitised control mice, multiple co-exposures to DEHP+OVA
reduced the IgG1 level and reduced the IgE/IgG2a ratio. This suggests that DEHP may attenuate
allergic sensitisation, as the IgE/IgG2a ratio has been shown to correlate with the degree of
anaphylaxis. Nevertheless, no effect of DEHP exposures was seen on inflammatory cells in
bronchoalveolar lavage fluid and on cytokine levels in spleen cell culture.
Conclusion: Data from humane and murine studies suggest that DEHP may attenuate the allergic
response. More studies are necessary in order to assess the size of this effect and to rule out the
underlying mechanism.
Background
The plastizicer di-(2-ethylhexyl) phthalate (DEHP) is
widely distributed in the environment and DEHP is, for
example, present in house dust [1], which also contains
allergens e.g. from house dust mites. Therefore, the poten-
tial allergy-promoting effect of DEHP and other phtha-
lates was evaluated in several recent studies [2]. Although
some of the epidemiological studies suggested that phtha-
lates promote allergic sensitisation [3,4], these findings
could not be confirmed in controlled animal studies [5-
7]. In mice, co-administration of DEHP with the model
allergen ovalbumin (OVA) stimulated production of the
immunoglobulins IgG1 and IgG2a but not IgE [6,7]. IgE
plays a central role in many allergic diseases, whereas the
role of IgG1 is less clear. IgG1 is a Th2-dependent anti-
body that may be anaphylactic in the mouse at high aller-
gen exposures [8,9]. On the other hand, it has been
proposed that IgG1 may constitute the murine equivalent
to the human IgG4 isotype, which may protect against
symptoms of allergy [10]. In mice, decreased IgG1 and
increased IgG2a have been associated with the develop-
ment of mucosal tolerance towards inhaled allergens [11].
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If DEHP selectively promote formations of IgG1 and
IgG2a without stimulating the IgE response, it could be
hypothesized that DEHP may be able to suppress elicita-
tion of an allergic response. This hypothesis is supported
by a recent study showing that house dust samples spiked
with DEHP (2 mg DEHP/gram dust) attenuated biomark-
ers of inflammation in the nasal mucosa of house dust
mite allergic subjects [12]. The aim of the present study is
to investigate whether repeated co-administrations of
DEHP and OVA to pre-sensitized mice attenuate the
allergy-related immune response. Assessments were based
on the levels of OVA-specific antibodies, ex vivo cytokine
levels, and the degree of allergic lung inflammation after
challenge with an OVA aerosol.
Methods
Mice
Inbred female BALB/cJ mice aged 5-6 weeks were pur-
chased from Taconic M&B, Ry, Denmark, and housed in
polypropylene cages (380 × 220 × 150 mm) with pine-
wood sawdust bedding (Lignocel S8, Brogaarden, Den-
mark). The cages, each housing up to 10 mice, were
furnished with bedding materials, gnaw sticks and card-
board tubes. The photo-period was from 6 a.m. to 6 p.m.,
and the temperature and mean relative humidity in the
animal room were 19-22°C and 43 ± 8% (SD), respec-
tively. Cages were sanitized twice weekly. Food (Altromin
no. 1324, Altromin, Lage, Germany) and tap water were
available ad libitum. Treatment of the animals followed
procedures approved by The Animal Experiment Inspec-
torate, Denmark.
Chemicals
DEHP (CAS 117-81-7, purity ≥98.0%) and polyethylene
glycol 400 (PEG 400, Ph. Eur. Grade, CAS 25322-68-3)
were from Merck, Hohenbrunn, Germany. The Al(OH)3
adjuvant formulation was Alhydrogel from Brenntag Bio-
sector, Frederikssund, Denmark. Chicken egg OVA (CAS
9006-59-1) was grade V (purity ≥98%) from Sigma-
Aldrich, St. Louis, MO, USA.
For use in cell culture, OVA was purified to remove endo-
toxins by means of an EndoTrap® red kit (Profos, Regens-
burg, Germany), according to the operating procedures of
the manufacturer. Purifying the OVA solution (10 mg/
mL) reduced the endotoxin content from 25.6 IU/mg to
1.2 IU/mg, i.e. by more than 95%.
Immunization procedure
Mice were immunized to OVA by intraperitoneal (i.p.)
injections of 1 μg OVA in combination with 270 μg
Al(OH)3 in 100 μl 0.9% saline on day 0 (cf. Fig 1). Mice
were boosted on day 7 and 14 with 0.1 μg OVA in combi-
nation with 270 μg Al(OH)3 in 100 μl 0.9% saline. The
animals were exposed 20 min to an aerosol of 0.2% OVA
on days 21 and 28 using a Pari Star nebulizer (PARI
GmbH, Starnberg, Germany). This sensitization proce-
dure was followed by seven once-weekly i.p. injections of
0.1 μg OVA alone or co-administration of 0.1 μg OVA and
100 μg DEHP (days 35, 42, 49, 56, 63, 70 and 77) in 50
μl PEG 400 vehicle (for details see [7]). Finally, mice were
exposed 20 min to an aerosol of 1% OVA on three consec-
utive days (day 91, 92, 93). Mice were euthanized on day
94, blood was collected, broncho-alveolar lavage (BAL)
was performed and the spleens were excides. BAL was per-
formed as described previous [13]. Briefly, the total BAL
cell numbers were achieved using a haemocytometer.
After cytospin (1000 × g, 4 min, RT), cells were stained by
May-Grünwald/Giemsa and were identified by standard
morphology. Cells were differentiated into neutrophils,
Protocol used for sensitization/de-sensitization of animals Figure 1
Protocol used for sensitization/de-sensitization of animals. Mice were sensitized by three i.p. injections of ovalbumin 
(OVA) and Al(OH)3 on day 0, 7 and 14, followed by two OVA aerosol challenges. Afterwards, the mice were treated either by 
i.p injections of OVA (control group) or a combination of OVA and di-(2-ethylhexyl) phthalate (DEHP) (immunotherapy 
group) on days 35, 42, 49, 56, 63, 70 and 77. Additionally, mice were challenged by an OVA aerosol on three consecutive days 
(91-93).
OVA + Al(OH)3
i.p.
0.2% OVA
inhalation
0           7        14         21         28       35         42        49        56         63         70        77           91-93
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eosinophils, epithelial cells, lymphocytes and macro-
phages. For each slide, 200 cells were counted using 400 ×
magnifications and the percentage of each cell type was
calculated.
Ex vivo lymphocyte culture and measurement of cytokine 
production
On termination of the experiment, the spleens were
excised and disintegrated by means of a 70 μm nylon cell
strainer (BD Falcon, from BD Falcon Biosciences, Bedford,
MA, USA). Cells were cultured in 24-well plates (Nunc,
Denmark) with 1.0 mL cell suspension per well (2.7 × 106
cells/mL). Growth medium was RPMI 1640 (Cambrex,
Belgium) supplemented with Nutridoma (1%), gentamy-
cin (50 μg/mL), and monothioglycerol (13.5 μL/L). Cells
were either unstimulated or stimulated with 1 mg/mL of
LPS-purified OVA. After 5 days, supernatants were har-
vested and analyzed for cytokines.
Levels of IL-4, IL-5, IL-10 and IFN-γ in BAL fluids were
assayed by ELISA kits (eBioscience, San Diego, USA)
according to manufacturer's description.
Antibody production
At the end of the experiment, mice were anaesthesized
and blood samples were collected by heart puncture. Sera
were assayed for content of OVA-specific IgE, IgG1 and
IgG2a. ELISAs were performed as described previously
[14].
Statistics
Antibody levels, numbers of inflammatory cells in BAL
fluid and ex vivo cytokine levels in the DEHP+OVA group
were compared pair-wise to the OVA control group by the
Mann-Whitney's U-test. A p-value of less than 0.05 was
considered statistically significant. Calculations were per-
formed using the Minitab Statistical Software, Release 14
Xtra (Minitab Inc., PA, USA).
Results
Antibody levels
With the purpose to evaluate the properties of DEHP as
adjuvant in immunotherapy, mice were repeatedly
exposed i.p. to a combination of DEHP and OVA. The
mice in the DEHP+OVA group had a significantly (p =
0.013) lower level of IgG1 than mice only exposed to OVA
(cf. Fig 2). Repeated DEHP exposures tend to have a sup-
pressive effect on IgE, although this suppression did not
reach statistical significance (p = 0.076). Furthermore,
there was a non-significant (p = 0.092) increase in the
IgG2a level in mice repeatedly exposed to DEHP+OVA
compared to the OVA control mice. The IgE/IgG2a ratio
was significantly (p = 0.024) lower in the DEHP+OVA
group compared to the OVA control group (Fig 2).
Splenocyte culture cytokines
As apparent from Fig 3, there were no differences in the
levels of IL-4, IL-5, IL-10 or IFNγ between the OVA and
DEHP+OVA groups. In the unstimulated control cultures,
levels of all cytokines were below the limit of detection.
BAL cell
Our protocol gave rise to a marked lung inflammation
dominated by high numbers of eosinophils both in the
OVA and DEHP+OVA groups as seen from Fig 4. Further-
more, a high number of neutrophils and lymphocytes
were present in both groups. Pair-wise comparisons
revealed that the number of neutrophils, eosinophils, epi-
thelial cells, lymphocytes and macrophages, respectively
were equal in both groups.
The epithelial cell numbers were low in both groups (data
not shown).
Discussion
This study hypothesized that DEHP can promote desensi-
tization to IgE mediated allergy. As an industrial chemical,
DEHP may have no direct potential as an adjuvant in
immunotherapy. However, if DEHP can promote desensi-
tization, this will bring additional support to results from
previous studies [6,7,15,16] which showed that DEHP did
not promote development of IgE mediated allergy. Also, if
DEHP may promote desensitization, it may be of interest
to study the adjuvant mechanisms with the purpose to
develop novel adjuvants for immunotherapy of IgE medi-
ated asthma and rhinitis. IgE mediated allergy is pro-
moted by T-helper (Th) 2 lymphocytes producing IL-4, IL-
Levels of OVA-specific antibodies Figure 2
Levels of OVA-specific antibodies. Levels of ovalbumin 
(OVA)-specific IgE, IgG1 and IgG2a antibodies in serum on 
day 94. Levels are medians of 9-10 mice with error bars rep-
resenting the 75th percentiles. Statistically difference between 
the OVA and OVA+DEHP group is indicated by * (p < 0.05).
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5 and IL-13 [17,18]. Immunotherapy is used to manage
IgE mediated rhinitis and asthma [17-19] by down-regu-
lation of the Th2 response by promoting a Th1 response
[19] due to production of interferon (IFN) γ, IL-2 and IL-
12 [17] and up-regulation of regulatory T lymphocytes,
producing IL-10 and transforming growth factor (TGF) β
[17,18]. As DEHP did not alter the level of IL-10 in the
present study, no conclusion can be drawn on the activity
of regulatory T lymphocyte.
We established an allergic airway inflammation in mice
dominated by eosinophilic inflammation and high levels
of IgE and IgG1 antibodies against the model allergen
OVA. Immunotherapy with multiple exposures to
DEHP+OVA significantly reduced the serum level of OVA-
specific IgG1 and the ratio IgE/IgG2a compared with
immunotherapy with OVA alone. Furthermore, border-
line to significant reduction was seen on IgE and border-
line increase of IgG2a level following multiple treatments
with DEHP+OVA exposure. The antibody profiles indi-
cated that DEHP promoted a mixed Th1/Th2 immune
response, whereas Al(OH)3, as expected, showed a pure
Th2-dominated profile. This is in accordance with previ-
ous observations with immunological studies of DEHP
[6]. In mice, decreased IgG1 and increased IgG2a have
been interpreted as development of mucosal tolerance
towards inhaled allergens [11]. In a recent study, a
decreased IgE/IgG2a ratio correlated well with reduced
anaphylaxis [20]; mice with a low IgE/IgG2a ratio had a
lower body temperature decrease than control animals
and the low IgE/IgG2a ratio protected the mice from
death upon allergen challenge [20].
The change in antibody pattern observed in the present
study suggests that DEHP may reduce the degree of aller-
gic sensitization in the mice. However, no effects of DEHP
were seen on the BAL cell counts, suggesting that the
desensitization effect of DEHP may be relatively weak.
Levels of cytokines in splenocyte culture supernatant Figure 3
Levels of cytokines in splenocyte culture supernatant. For details cf. the method section. Levels are mean with SEM of 
9-10 mice.
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Nevertheless, our results are in line with a recent study by
Deutschle and co-workers who exposed house dust mite
(HDM) allergic subjects to HDM-containing dust samples
spiked with DEHP (2 mg DEHP/gram dust) [12]. DEHP
reduced the levels of the inflammatory cytokines, G-CSF
and IL-6, in the nasal secretions after nasal challenge with
HDM, which suggests that DEHP attenuates allergic
inflammation. In that study, no difference was seen on
self-reported symptoms also suggesting a weak effect.
Conclusion
The very few studies investigating the desensitisation
potential of DEHP suggest that DEHP may attenuate aller-
gic sensitization. However, further studies are needed in
order to draw a firm conclusion, assessing the size of the
effect, and to reveal the immunological mechanisms of
the desensitization.
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